Melissa Yacur, MD
Medical Oncology · Fairfax, VANPI 1801283676
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $230 of the $306 with a category attached, or 75.2%. 6 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.8% of the total. Reporting peaked in 2020 at $120 and has fallen 79.3% since, to $25 in 2024. That places this record below the midpoint for medical oncology clinicians in VA, where the typical reported total is $926.
Across 6 payments — averaging $51.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$85
- Incyte Corporation$76
- Beigene USA, Inc.$64
- Epizyme, Inc.$40
- Gilead$25
- Amgen$16
Across 3 payments — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$30K
What the payments were for
- Food & beverage$23075%
- Education$7625%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $85 |
| Incyte Corporation | 1 | $76 |
| Beigene USA, Inc. | 1 | $64 |
| Epizyme, Inc. | 1 | $40 |
| Gilead | 1 | $25 |
| Amgen | 1 | $16 |
How this compares
$306 in reported general payments places this provider in the 30th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 29 | $480,804 |
| Letrozole | 159 | $2,727 |
| Exemestane | 12 | $882 |
| Dexamethasone | 29 | $561 |
| Tamoxifen Citrate | 18 | $443 |
| Anastrozole | 19 | $423 |
| Ondansetron Hcl | 30 | $341 |
| Prochlorperazine Maleate | 17 | $177 |
| Oxycodone Hcl | 15 | $176 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 15 | $175 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $116 |
| Famotidine | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Fairfax
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Nagla Abdel KarimFairfax$131K
- Lauren MauroFairfax$53K
- Donald TrumpFairfax$20K
- Timothy CannonFairfax$11K
- Arthur WinerFairfax$10K
- Danijela JelovacFairfax$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.